Watch Ticker

Denali Therapeutics Inc. Common Stock

Go to Denali Therapeutics Inc. Common Stock Website

$14.29

-0.15 (-1.04%)

Live

Previous Close

$14.44

Day Range

$13.82 - $14.41

Previous Day Range

$13.31 - $14.525

Market Cap

$2.0 billion USD

Day Vol.

2.1 million

Previous Day Vol.

2.1 million

Currency

USD

Primary Exchange

Nasdaq

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant ...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

N/A - Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program

Denali Therapeutics has initiated a rolling submission of a biologics license application (BLA) for accelerated approval of tividenofusp alfa for the treatment of Hunter syndrome (MPS II). The company also has positive ongoing interactions with the FDA on the development of DNL126 for Sanfilippo syndrome type A (MPS IIIA) through the START program.

Related tickers: DNLI.

Read Full Article

Delveinsight - Mucopolysaccharidosis Market Analysis Across 7MM — Unveiling Growth Opportunities Across Different Types | DelveInsight

The mucopolysaccharidosis market is witnessing a surge in innovation, driven by cutting-edge gene therapies, enzyme replacement treatments, and novel drug developments. The market is poised for exponential growth with rising awareness, early diagnosis, and increasing investments in rare disease research.

Related tickers: BMRN, TAK, DNLI, RGNX, RARE.

Read Full Article

Trending Tickers

Please sign in to view